Related Experiment Videos
Elevated serum surfactant protein A and D in pulmonary alveolar microlithiasis.
Hiroki Takahashi1, Hirofumi Chiba, Masanori Shiratori
1The Third Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
Respirology (Carlton, Vic.)
|April 26, 2006
Summary
Pulmonary alveolar microlithiasis (PAM) is a rare lung disease. Surfactant proteins A and D may serve as biomarkers to track PAM progression.
Area of Science:
- Pulmonary Medicine
- Rare Diseases
- Biomarker Discovery
Background:
- Pulmonary alveolar microlithiasis (PAM) is an exceptionally rare interstitial lung disease.
- Characterized by diffuse calcispherite deposition within the alveoli, leading to respiratory compromise.
Observation:
- Two cases of PAM presented with significantly elevated serum concentrations of surfactant protein-A (SP-A) and surfactant protein-D (SP-D).
- These elevated levels demonstrated a positive correlation with disease progression in the observed patients.
Findings:
- Serum levels of SP-A and SP-D were markedly elevated in patients with pulmonary alveolar microlithiasis.
- The concentrations of SP-A and SP-D showed a trend of increasing as the disease advanced.
Implications:
- SP-A and SP-D show potential as non-invasive serum biomarkers for monitoring PAM activity.
- These findings could aid in the clinical management and therapeutic strategy development for PAM patients.
- Further research is warranted to validate SP-A and SP-D as reliable indicators of PAM progression.